FY2026 EPS Estimates for Sanofi Boosted by Erste Group Bank

Sanofi (NASDAQ:SNY) – Equities researchers at Erste Group Bank increased their FY2026 earnings per share estimates for shares of Sanofi in a report released on Thursday, April 2nd. Erste Group Bank analyst H. Engel now forecasts that the company will earn $4.92 per share for the year, up from their prior estimate of $4.91. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Erste Group Bank also issued estimates for Sanofi’s FY2027 earnings at $5.23 EPS.

A number of other equities analysts have also commented on the stock. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Barclays lowered shares of Sanofi from an “overweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Citigroup initiated coverage on shares of Sanofi in a report on Tuesday, January 27th. They set a “neutral” rating on the stock. Bank of America downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Finally, Weiss Ratings downgraded shares of Sanofi from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, March 23rd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $61.50.

Sanofi Stock Down 0.1%

Shares of NASDAQ SNY opened at $47.08 on Thursday. The company has a market cap of $114.83 billion, a P/E ratio of 13.08, a PEG ratio of 1.17 and a beta of 0.42. The firm has a 50-day simple moving average of $46.47 and a two-hundred day simple moving average of $48.00. Sanofi has a 1 year low of $43.32 and a 1 year high of $55.73. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brighton Jones LLC increased its holdings in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after buying an additional 1,869 shares in the last quarter. AQR Capital Management LLC increased its holdings in Sanofi by 107.2% in the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after buying an additional 15,791 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Sanofi by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after buying an additional 752 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in Sanofi by 5.4% in the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after buying an additional 347 shares in the last quarter. Finally, CW Advisors LLC increased its holdings in Sanofi by 110.7% in the second quarter. CW Advisors LLC now owns 13,753 shares of the company’s stock valued at $664,000 after buying an additional 7,226 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.